Latest News2023-07-31T14:16:37-04:00

Virica Biotech Announces R&D Partnership with Oxford BioMedica

OTTAWA ,Canada– January 24th, 2022 – Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica's next generation lentiviral vector gene therapies using Virica's Viral Sensitizers (VSEs™). DOWNLOAD FULL PRESS RELEASE HERE

January 24th, 2022|

Virica Biotech Raises Series A Financing & Expands Operations to Support Clients’ Manufacturing of Viral Medicines

OTTAWA – October 4, 2021 – Virica Biotech Inc., a leading life science developer of solutions for scaling of viral medicines, announced today the first closing of its Series A financing. The round, led by Dynamk Capital, is expected to close with additional investors by the end of Q4-2021. The investment strengthens Virica’s already impressive growth trajectory, as it gears up to become a premier manufacturing partner for global viral medicine producers. The investment will be used to expand Virica’s operations with the opening of a new lab facility, that is part of the Ottawa Health Innovation Hub. Watch the grand opening here. [...]

October 27th, 2021|

Virica Biotech: Enabling Vaccine Development to Fight Against COVID-19

March 14, 2020—As the world deals with COVID-19, now officially deemed a pandemic, many groups are racing against the clock to develop vaccines against the novel coronavirus. The development and manufacturing of effective vaccines is a laborious and challenging task for a variety of reasons. In the pandemic situation that we and our loved ones are facing today, creating, manufacturing, testing, and delivering novel vaccines for a global population of more than 7 billion is truly a daunting challenge. As researchers and global citizens, we offer our heartfelt thanks to healthcare workers, researchers, governments, and biotechnology companies, who are currently [...]

November 10th, 2020|

Virica’s Founder and CEO Dr. Jean-Simon Diallo Spoke with CBC’s All in a Day, Alan Neal

Virica’s Founder and CEO Dr. Jean-Simon Diallo spoke in an interview with CBC on All in a Day with Alan Neal on fighting the current COVID-19 pandemic by speeding up the process of mass-producing vaccines. Virica’s VSE technology which was spun out of the Ottawa Hospital Research Institute aims to overcome the manufacturing challenges that exist in producing viruses.

November 10th, 2020|

Virica’s Founder and CEO Dr. Jean-Simon Diallo interviewed by CTV Ottawa Morning

Virica’s Founder and CEO Dr. Jean-Simon Diallo discusses his latest virology research at the Ottawa Hospital Research Institute, which focuses on Covid-19 and is funded by the Ontario Government, with CTV Ottawa Morning. His team is using a biosensor that detects the interaction with the virus and its receptor which will allow them to rapidly test small molecules and drugs for their ability to block the virus which is crucial not only for this pandemic, but also in the future.

November 10th, 2020|



Breakthrough technology is both intimidating and exhilarating

Innovation is needed achieve the promise of advanced therapies and to make vaccines accessible to all. We’re here to help you realize this goal by providing our expertise and experience. We’re here to guide the way. Let’s Talk

Go to Top